Minimal Ocular Findings in a Patient with Best Disease Caused by the c.653G>A Mutation in BEST1
Authors:
B. Kousal 1; F. Chakarova 2; G. C. Black 3; S. Ramsden 3; H. Langrová 4; P. Lišková 5
Authors place of work:
Oční klinika, 1. lékařská fakulta, Univerzita Karlova a Všeobecná fakultní nemocnice, Praha, přednosta doc. MUDr. Bohdana Kalvodová, CSc.
1; Institute of Ophthalmology, UCL, London, Velká Británie, ředitel, prof. Philip J. Luther, BSc, MBBS, FRCP, FRCPath, FRCOphth
2; Genetic Medicine Research Group, Manchester Biomedical Research Centre, Manchester Academic Health Sciences Centre, University of Manchester and Central Manchester Foundation Trust, St Mary’s Hospital, Manchester M13 9WL, Velká Británie, ředitel prof. Gra
3; Oční klinika, Lékařská fakulta v Hradci Králové, Univerzita Karlova, Praha, přednosta prof. MUDr. Pavel Rozsíval, CSc.
4; Laboratoř biologie a patologie oka, Ústav dědičných metabolických poruch, 1. lékařská fakulta, Univerzita Karlova a Všeobecná fakultní nemocnice, Praha, přednosta doc. MUDr. Viktor Kožich, CSc.
5
Published in the journal:
Čes. a slov. Oftal., 67, 2011, No. 5-6, p. 170-174
Category:
Case Reports
Summary
Purpose:
To describe the phenotype in an asymptomatic 64-year-old patient with family history of Best disease and to identify the disease causing variant in the BEST1 gene.
Methods:
Detailed ocular examination of the proband including spectral-domain optical coherence tomography (SD-OCT), fluorescein angiography and electrooculography was performed. Direct sequencing approach was used to screen the whole coding sequence of 11 exons of BEST1.
Results:
An early vitelliform stage of Best disease presenting as a small yellowish spot in the macula was observed in the right eye. The fundus appearance in the left eye was normal. SD-OCT of the right macula revealed hypodense space between the retinal pigment epithelium and the neuroretinal layer. Arden ratio was bilaterally mildly reduced; 1.36 in the right and 1.3 in the left eye. Molecular genetic analysis identified a heterozygous change c.653G>A (p.Arg218His) as the disease-causing variant.
Conclusion:
Here we report for the first time a phenotype-genotype correlation in a Czech patient with Best disease. SD-OCT is a fast method that may show the presence of small pathological changes. The screening of BEST1 gene enables identification of disease-causing variants in asymptomatic individuals with normal fundus appearance and thus improves counseling to the affected families.
Key words:
Best disorder, BEST1, mutation, optic coherence tomography, phenotype
Zdroje
1. Andrade, RE., Farah, ME., Costa, RA.: Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in best disease. Am J Ophthalmol. 2003; 136: 1179–1181.
2. Antonarakis, SE.: Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat, 1998; 11: 1–3.
3. Booij, JC., Boon, CJ., van Schooneveld, MJ., et al.: Course of visual decline in relation to the Best1 genotype in vitelliform macular dystrophy. Ophthalmology, 2010; 117: 1415–1422.
4. Boon, CJ., Klevering, BJ., Keunen, JE., et al.: Fundus autofluorescence imaging of retinal dystrophies. Vision Res. 2008; 48: 2569–2577.
5. Boon, CJ., Klevering, BJ., den Hollander, AI., et al.: Clinical and genetic heterogeneity in multifocal vitelliform dystrophy. Arch Ophthalmol, 2007; 125: 1100–1106.
6. Boon, CJ., Klevering, BJ., Leroy, BP., et al.: The spectrum of ocular phenotypes caused by mutations in the BEST1 gene. Prog Retin Eye Res. 2009; 28: 187–205.
7. Burgess, R., MacLaren, RE., Davidson, AE., et al.: ADVIRC is caused by distinct mutations in BEST1 that alter pre-mRNA splicing. J Med Genet. 2009; 46: 620–625.
8. Burgess, R., Millar, ID., Leroy, BP., et al.: Biallelic mutation of BEST1 causes a distinct retinopathy in humans. Am J Hum Genet, 2008, 82: 19–31.
9. Cross, HE., Bard, L.: Electro-oculography in Best’s macular dystrophy. Am J Ophthalmol. 1974; 77: 46–50.
10. Davidson, AE., Millar, ID., Urquhart, JE., et al.: Missense mutations in a retinal pigment epithelium protein, bestrophin-1, cause retinitis pigmentosa. Am J Hum Genet. 2009; 85: 581–592.
11. den Dunnen, JT., Antonarakis, SE.: Nomenclature for the description of human sequence variations. Hum Genet. 2001; 109: 121–124.
12. Esumi, N., Kachi, S., Hackler, L., et al.: BEST1 expression in the retinal pigment epithelium is modulated by OTX family members. Hum Mol Genet. 2009; 18: 128–141.
13. Godel, V., Chaine, G., Regenbogen, L., et al.: Best’s vitelliform macular dystrophy. Acta Ophthalmol Suppl. 1986; 175: 1–31.
14. Chung, MM., Oh, KT., Streb, LM., et al.: Visual outcome following subretinal hemorrhage in Best disease. Retina. 2001; 21: 575–580.
15. Jarc-Vidmar, M., Kraut, A., Hawlina, M.: Fundus autofluorescence imaging in Best’s vitelliform dystrophy. Klin Monbl Augenheilkd. 2003; 220: 861–867.
16. Lacassagne, E., Dhuez, A., Rigaudiere, F., et al.: Phenotypic variability in a French family with a novel mutation in the BEST1 gene causing multifocal best vitelliform macular dystrophy. Mol Vis. 2011; 17: 309–322.
17. Leu, J., Schrage, NF., Degenring. RF.: Choroidal neovascularisation secondary to Best’s disease in a 13-year-old boy treated by intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2007; 245: 1723–1725.
18. Lotery, AJ., Munier, FL., Fishman, GA., et al.: Allelic variation in the VMD2 gene in Best disease and age-related macular degeneration. Invest Ophthalmol Vis Sci. 2000; 41: 1291–1296.
19. Marchant, D., Gogat, K., Boutboul, S., et al.: Identification of novel VMD2 gene mutations in patients with Best vitelliform macular dystrophy. Hum Mutat. 2001; 17: 235.
20. Marchant, D., Yu, K., Bigot, K., et al.: New VMD2 gene mutations identified in patients affected by Best vitelliform macular dystrophy. J Med Genet. 2007; 44: e70.
21. Marmor, MF., Brigell, MG., McCulloch, DL., et al.: ISCEV standard for clinical electro-oculography (2010 update). Doc Ophthalmol. 2011; 122: 1–7.
22. Marmorstein, AD., Cross, HE., Peachey, NS.: Functional roles of bestrophins in ocular epithelia. Prog Retin Eye Res. 2009; 28: 206–226.
23. Marquardt, A., Stohr, H., Passmore, LA., et al.: Mutations in a novel gene, VMD2, encoding a protein of unknown properties cause juvenile-onset vitelliform macular dystrophy (Best’s disease). Hum Mol Genet. 1998; 7: 1517–1525.
24. Miller, SA.: Multifocal Best’s vitelliform dystrophy. Arch Ophthalmol. 1977; 95: 984–990.
25. Mohler, CW., Fine, SL.: Long-term evaluation of patients with Best’s vitelliform dystrophy. Ophthalmology. 1981; 88: 688–692.
26. Montero, JA., Ruiz-Moreno, JM., De La Vega, C.: Intravitreal bevacizumab for adult-onset vitelliform dystrophy: a case report. Eur J Ophthalmol. 2007; 17: 983–986.
27. Pianta, MJ., Aleman, TS., Cideciyan, AV., et al.: In vivo micropathology of Best macular dystrophy with optical coherence tomography. Exp Eye Res. 2003; 76: 203-211.
28. Pollack, K., Kreuz, FR., Pillunat, LE.: [Best’s disease with normal EOG. Case report of familial macular dystrophy]. Ophthalmologe, 2005; 102: 891–894.
29. Ponjavic, V., Eksandh, L., Andreasson, S., et al.: Clinical expression of Best’s vitelliform macular dystrophy in Swedish families with mutations in the bestrophin gene. Ophthalmic Genet. 1999; 20: 251–257.
30. Querques, G., Regenbogen, M., Quijano, C., et al.: High-definition optical coherence tomography features in vitelliform macular dystrophy. Am J Ophthalmol. 2008; 146: 501–507.
31. Querques, G., Regenbogen, M., Soubrane, G., et al.: High-resolution spectral domain optical coherence tomography findings in multifocal vitelliform macular dystrophy. Surv Ophthalmol. 2009; 54: 311–316.
32. Querques, G., Zerbib, J., Santacroce, R., et al.: The spectrum of subclinical Best Vitelliform Macular Dystrophy in subjects with mutations in BEST1 gene. Invest Ophthalmol Vis Sci. 201; 52: 4678–4684.
33. Querques, G., Zerbib, J., Santacroce, R., et al.: Functional and clinical data of Best vitelliform macular dystrophy patients with mutations in the BEST1 gene. Mol Vis. 2009; 15: 2960–2972.
34. Schatz, P., Bitner, H., Sander, B., et al.: Evaluation of macular structure and function by OCT and electrophysiology in patients with vitelliform macular dystrophy due to mutations in BEST1. Invest Ophthalmol Vis Sci. 2010; 51: 4754–4765.
35. Sohn, EH., Francis, PJ., Duncan, JL., et al.: Phenotypic variability due to a novel Glu292Lys variation in exon 8 of the BEST1 gene causing best macular dystrophy. Arch Ophthalmol. 2009; 127: 913–920.
36. Spaide, R.: Autofluorescence from the outer retina and subretinal space: hypothesis and review. Retina, 2008; 28: 5–35.
37. Spaide, RF., Noble, K., Morgan, A., et al.: Vitelliform macular dystrophy. Ophthalmology, 2006; 113: 1392–1400.
38. Testa, F., Rossi, S., Passerini, I., et al.: A normal electro-oculography in a family affected by Best disease with a novel spontaneous mutation of the BEST1 gene. Br J Ophthalmol. 2008; 92: 1467–1470.
39. Wabbels, B., Preising, MN., Kretschmann, U., et al.: Genotype-phenotype correlation and longitudinal course in ten families with Best vitelliform macular dystrophy. Graefes Arch Clin Exp Ophthalmol. 2006; 244: 1453–1466.
Štítky
OphthalmologyČlánok vyšiel v časopise
Czech and Slovak Ophthalmology
2011 Číslo 5-6
Najčítanejšie v tomto čísle
- Comparison of Keratometric Values and Corneal Eccentricity of Myopia, Hyperopia and Emmetropia
- Minimal Ocular Findings in a Patient with Best Disease Caused by the c.653G>A Mutation in BEST1
- AquaLase Method – Influence to the Secondary Cataract Appearance and its Safety
- Suprachoroid Hemorrhage without the Connection to the Surgical Procedure